PLOD2 and nonpapillary renal cell carcinoma: Subsequently, we confirmed that the hypoxia-PLOD2 axis governed the preferential activation of DCLK1-L in ccRCC by activating β-catenin, as shown by both loss- and gain-of-function investigations.